Teladoc, Inc. (NYSE:TDOC)‘s stock had its “outperform” rating reaffirmed by investment analysts at CIBC in a research note issued to investors on Tuesday. They currently have a $45.00 target price on the health services provider’s stock, up from their prior target price of $40.00. CIBC’s price target would indicate a potential upside of 48.03% from the company’s current price.

A number of other brokerages have also commented on TDOC. Robert W. Baird lowered shares of Teladoc from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $14.00 to $36.00 in a report on Monday, September 18th. KeyCorp reissued a “buy” rating and issued a $37.00 price target on shares of Teladoc in a report on Sunday, September 17th. Zacks Investment Research raised shares of Teladoc from a “sell” rating to a “buy” rating and set a $38.00 price target on the stock in a report on Wednesday, October 4th. BidaskClub lowered shares of Teladoc from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $39.00 target price on shares of Teladoc in a report on Saturday, September 30th. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $39.00.

Shares of Teladoc (TDOC) traded up $2.00 during trading hours on Tuesday, hitting $30.40. 1,820,400 shares of the stock were exchanged, compared to its average volume of 925,269. Teladoc has a 1 year low of $15.65 and a 1 year high of $37.55. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08.

Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.25). The company had revenue of $68.70 million during the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. Teladoc’s quarterly revenue was up 112.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.33) EPS. research analysts expect that Teladoc will post -1.57 EPS for the current fiscal year.

WARNING: “CIBC Reaffirms Outperform Rating for Teladoc, Inc. (TDOC)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/21/cibc-reaffirms-outperform-rating-for-teladoc-inc-tdoc.html.

In other Teladoc news, CEO Jason N. Gorevic sold 20,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $33.47, for a total transaction of $669,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Mark Hirschhorn sold 10,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $34.04, for a total transaction of $340,400.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 135,000 shares of company stock worth $4,408,700. 4.47% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in TDOC. Janus Henderson Group PLC purchased a new stake in Teladoc during the 2nd quarter valued at $58,287,000. Bamco Inc. NY boosted its position in Teladoc by 751.9% during the 3rd quarter. Bamco Inc. NY now owns 1,455,900 shares of the health services provider’s stock valued at $48,263,000 after buying an additional 1,285,000 shares during the period. BlackRock Inc. boosted its position in Teladoc by 42.9% during the 2nd quarter. BlackRock Inc. now owns 3,844,402 shares of the health services provider’s stock valued at $133,400,000 after buying an additional 1,154,852 shares during the period. Victory Capital Management Inc. purchased a new stake in Teladoc during the 3rd quarter valued at $35,360,000. Finally, JPMorgan Chase & Co. boosted its position in Teladoc by 65.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,663,600 shares of the health services provider’s stock valued at $92,426,000 after buying an additional 1,057,065 shares during the period.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.